Welcome to the Leading Forum for Advancing Preclinical Autoimmune & Inflammatory Models
Breakthroughs in autoimmune and inflammatory therapies demand models that truly mirror human biology. To deliver life-changing treatments, the entire industry must align on translational science like never before.
The inaugural Autoimmune & Inflammatory Models Summit arrives at a pivotal moment. With the FDA accelerating its move beyond animal testing and investment pouring into this space, we're bringing together drug developers, regulators and solution providers to redefine preclinical success.
Join leaders from Bristol Myers Squibb, Takeda, Seismic Therapeutics and more, to bring assurance to your model design and selection process against the 90% failure rate plaguing autoimmune and inflammatory drug development.
Access the Full Event Guide:
- Meet the Speakers
- View Full Session Details
- Explore Registration Options
Join Us To:
Harness autoimmune and inflammatory model translatability with oncology insights. Learn from Takeda’s case studies to adapt advanced in vitro platforms and predict clinical endpoints for next-generation therapies
Explore cutting-edge in vitro and humanized mouse models to redefine chronic disease targeting. Learn how AbbVie, Astellas Pharma and GentiBio leverage these advances for breakthrough validation
Navigate the upcoming FDA requirements and decipher a strategic plan towards an ex vivo future and confidence for successful IND submissions
Discover how machine learning redesigns therapeutic proteins to evade immunogenicity. Learn breakthrough strategies from Cyrus Biotechnology and Seismic Therapeutics to overcome this critical development bottleneck
Accompany companies like AbbVie and Pfizer to prioritize biologically relevant models over therapeutic convenience. Shift to a recapitulation-first approach and transform your preclinical outcomes
Who Will You Meet?
This summit unites preclinical and translational scientists, directors, managers and other preclinical experts from leading autoimmune and inflammatory drug developers to tackle the critical bottleneck of poor model translatability.
Access the Full Event Guide:
- Meet the Speakers
- View Full Session Details
- Explore Registration Options